View more in
Diseases & Treatments

New Safety Warnings on JAK Inhibitors, Used to Treat Arthritis and Other Inflammatory Conditions

Cover picture for the articleOn Monday, September 1, the U.S. Food and Drug Administration (FDA) announced that Xeljanz (tofacitinib), Xeljanz XR, Oluminant (baricitinib), and Rinvoq (upadacitinib) will be required have new and updated warnings about an increased risk of heart-related events such as heart attack or stroke, cancer, blood clots, and death. All three...

Comments / 1

Comments / 0